2021 Society Meeting Program

 R.O.C.K. Society Meeting at the AUA

IMPORTANT NOTE: All times are listed in Pacific Time

Monday, September 13, 2021
8:00 - 8:05 AM
Andrew D. Rule, MD, ROCK Society President
Session I: Epidemiology of Kidney Stones
Marcelino Rivera
8:05 - 8:20 AM
Trends in the Incidence and Prevalence of Kidney Stones
Charles D. Scales, Jr.
Duke Health System-Urology Division, Durham, NC
8:20 - 8:35 AM
Risk Factors for Kidney Stones and Their Recurrence
Ryan Hsi
Vanderbilt University Medical Center, Nashville, TN
8:35 - 9:00 AM
Questions and Answers
Session 2: Medical Management of Stone Formers
Andrew Rule
9:00 - 9:12 AM
Improving Quality of Life in Stone Formers
Kristina L. Penniston
UW School of Med and Public Health, Madison, WI
9:12 - 9:24 AM
Opioids in the Management of Patients with Kidney Stones
Nicole Lara Miller
Vanderbilt Univ Med Ctr, Nashville, TN
9:24 - 9:36 AM
Options for Potassium Citrate Therapy
Kymora Scotland
University of California, Los Angeles, CA
9:36 - 9:48 AM
Emerging Treatments for Hyperoxaluria
John C. Lieske
Mayo Clinic, Rochester, MN
9:48 - 10:00 AM
Medical Treatment of Cystinuria (Non-CME)
David S. Goldfarb
New York Harbor VA Healthcare System, New York, NY
10:00 - 10:15 AM
Session 3: Surgical Management of Stone Formers
Roger L. Sur
10:15 - 10:27 AM
Dusting versus Basketing
Mitchell R. Humphreys
Mayo Clinic, Phoenix, AZ
10:27 - 10:39 AM
New Devices for PCNL Lithotripsy
Tim Large
Indiana University Health, Indianapolis, IN
Session 4: The Great PCNL Debates
Jodi Antonelli
11:15 - 11:25 AM
PCNL Should Be in the Supine Position
Roger L. Sur
University of California San Diego, San Diego, CA
11:25 - 11:35 AM
PCNL Should Be in the Prone Position
Michael E. Lipkin
Duke University Medical Center, Durham, NC
11:35 - 11:45 AM
PCNL Can be Outpatient
Seth K. Bechis
University of California San Diego, San Diego, CA
11:45 - 11:55 AM
PCNL Should Always be Inpatient
Karen Stern
Mayo Clinic, Phoenix, AZ
11:55 - 12:00 PM
Questions and Answers
12:00 - 1:00 PM
Sponsored Lunch Program (Non-CME)
Updates on Clinical Development Program for Nedosiran: An Investigational Treatment for Primary Hyperoxaluria
Speaker: John Karafilidis, VP Medical Affairs

An overview of the clinical development program for nedosiran, an investigational RNAi therapy for the treatment of patients with Primary Hyperoxaluria (PH) by Dicerna Pharmaceuticals. Presentation will focused on results from the recently completed PHYOX 2 trial (in patients with PH1 and PH2), as well as providing and will provide an overview of ongoing trials with nedosiran.

Supported by Dicerna Pharmaceuticals
1:00 PM
Closing Remarks
Andrew D. Rule, MD, ROCK Society President